Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
The Application of DNA Methylation in Cancers
share announcement

The Application of DNA Methylation in Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: closed (15 October 2022) | Viewed by 5060

Special Issue Editors

Dr. Tomasz K. Wojdacz

E-Mail Website
Guest Editor
1. Independent Clinical Epigenetics Laboratory, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Zachodniopomorskie, Poland
2. Aarhus Institute of Advanced Studies, Aarhus University, 8000 Aarhus C, Denmark
Interests: epigenetics; biomarker; cancer; IVD; patent
Dr. Matthew Rose-Zerilli

E-Mail Website
Guest Editor
1. Cancer Sciences Unit, University of Southampton, Southampton, UK
2. Institute for Life Sciences, University of Southampton, Southampton, UK
Interests: epigenetics; cancer; evolution; genomics

Special Issue Information

Dear Colleagues,

DNA methylation is one of the most common covalent modifications of nucleotides in the DNA strand in humans. This modification has been known since the beginning of the last century and its significance in the development of not only cancer but also almost all types of diseases has been demonstrated in a vast number of publications. However, it is only recently that DNA methylation has begun to impact medical practice. With the personalized approach to patient treatment becoming a reality in clinical work, disease-related methylation changes are a rich source of biomarkers, helpful in the assessment of individual predisposition to disease and suitable for the early detection of disease, as well as being used as prognostic and predictive biomarkers for clinical disease management. Moreover, as DNA methylation is an enzymatic process and thus, potentially reversible, an increasing number of compounds targeting disease-related methylation changes are being tested in clinical trials. With the above in mind, the aim of this Special Issue is to feature papers that show translation applications of DNA methylation in both in vitro diagnostics and the treatment of cancer. We would like to invite both reviews and original research papers for submissions with the deadline at the end of 2021.

Dr. Tomasz K. Wojdacz
Dr. Matthew Rose-Zerilli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • epigenetics
  • DNA methylation
  • biomarker
  • diagnostics
  • IVD
  • personalized medicine

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1657 KiB  
Article
Long-Term Treatment with Bortezomib Induces Specific Methylation Changes in Differentiated Neuronal Cells
by Karolina Łuczkowska, Olga Taryma-Leśniak, Jan Bińkowski, Katarzyna E. Sokołowska, Dominik Strapagiel, Justyna Jarczak, Edyta Paczkowska, Bogusław Machaliński and Tomasz K. Wojdacz
Cancers 2022, 14(14), 3402; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14143402 - 13 Jul 2022
Cited by 2 | Viewed by 1685
Abstract
Bortezomib (BTZ) is proteasome inhibitor, effectively used in the treatment of multiple myeloma, but frequently discontinued due to peripheral neuropathy, which develops in patients after consecutive treatment cycles. The molecular mechanisms affected by BTZ in neuronal cells, which result in neuropathy, remain unknown. [...] Read more.
Bortezomib (BTZ) is proteasome inhibitor, effectively used in the treatment of multiple myeloma, but frequently discontinued due to peripheral neuropathy, which develops in patients after consecutive treatment cycles. The molecular mechanisms affected by BTZ in neuronal cells, which result in neuropathy, remain unknown. However, BTZ is unlikely to lead to permanent morphological nerve damage, because neuropathy reverses after discontinuation of treatment, and nerve cells have very limited renewal capacity. We have previously shown that BTZ induces methylation changes in SH-SY5Y cells, which take part in the development of treatment resistance. Here, we hypothesized that BTZ affects the methylomes of mature neurons, and these changes are associated with BTZ neurotoxicity. Thus, we studied methylomes of neuronal cells, differentiated from the LUHMES cell line, after cycles of treatment with BTZ. Our results show that BTZ induces specific methylation changes in mature neurons, which are not present in SH-SY5Y cells after BTZ treatment. These changes appear to affect genes involved in morphogenesis, neurogenesis, and neurotransmission. Furthermore, identified methylation changes are significantly enriched within binding sites of transcription factors previously linked to neuron physiology, including EBF, PAX, DLX, LHX, and HNF family members. Altogether, our results indicate that methylation changes are likely to be involved in BTZ neurotoxicity. Full article
(This article belongs to the Special Issue The Application of DNA Methylation in Cancers)
►▼ Show Figures

Figure 1

14 pages, 2388 KiB  
Article
DNA Methylation-Based Estimates of Circulating Leukocyte Composition for Predicting Colorectal Cancer Survival: A Prospective Cohort Study
by Xīn Gào, Yan Zhang, Xiangwei Li, Lina Jansen, Elizabeth Alwers, Melanie Bewerunge-Hudler, Matthias Schick, Jenny Chang-Claude, Michael Hoffmeister and Hermann Brenner
Cancers 2021, 13(12), 2948; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13122948 - 12 Jun 2021
Cited by 2 | Viewed by 2264
Abstract
Leukocytes are involved in the progression of colorectal cancer (CRC). The proportion of six major leukocyte subtypes can be estimated using epigenome-wide DNA methylation (DNAm) data from stored blood samples. Whether the composition of circulating leukocytes can be used as a prognostic factor [...] Read more.
Leukocytes are involved in the progression of colorectal cancer (CRC). The proportion of six major leukocyte subtypes can be estimated using epigenome-wide DNA methylation (DNAm) data from stored blood samples. Whether the composition of circulating leukocytes can be used as a prognostic factor is unclear. DNAm-based leukocyte proportions were obtained from a prospective cohort of 2206 CRC patients. Multivariate Cox regression models and survival curves were applied to assess associations between leukocyte composition and survival outcomes. A higher proportion of lymphocytes, including CD4+ T cells, CD8+ T cells, B cells, and NK cells, was associated with better survival, while a higher proportion of neutrophils was associated with poorer survival. CD4+ T cells outperformed other leukocytes in estimating the patients’ prognosis. Comparing the highest quantile to the lowest quantile of CD4+ T cells, hazard ratios (95% confidence intervals) of all-cause and CRC-specific mortality were 0.59 (0.48, 0.72) and 0.59 (0.45, 0.77), respectively. Furthermore, the association of CD4+ T cells and prognosis was stronger among patients with early or intermediate CRC or patients with colon cancer. In conclusion, the composition of circulating leukocytes estimated from DNAm, particularly the proportions of CD4+ T cells, could be used as promising independent predictors of CRC survival. Full article
(This article belongs to the Special Issue The Application of DNA Methylation in Cancers)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop